Colorectal IHC portfolio

^References:

^{1. NCCN Guidelines Version 1.2017. Genetic/Familial High Risk Assessment: Colorectal. NCCN Clinical Practice Guideline in Oncology. NCCN.org.}

^{2. Evaluation of Genomic Applications in Practice and Prevention Working Group. (2009). Recommendations from the EGAPP working group: genetic testing strategies in thenewly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.}

^{3. ASCO, A.C.A, 2016. Guideline on the Evaluation of Molecular Markersfor ColorectalCancer Expert Panel Draft Recommendations Summary for Open CommentPeriodAmerican Society for Clinical Pathology, the College of AmericanPathologists. the Association for Molecular Pathology, and the American Society of Clinical Oncology<http://www.amp.org/committees/clinicalpractice/documents/20150327CRCMMDraftRecommendationsforOCP-UPDATEDfinaldraft 001.pdf>.}

^{4. NICE, 2017. Molecular Testing Strategies for Lynch Syndrome in People with Colorectal Cancer. National Institute for Health and Care Excellence. http://www.nice.org.uk/guidance/dg27/chapter/1-Recommendations.}

^{5. Hampel H: Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer 15:423-427, 2016}

^{6. Roth, R. M. et al. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. Am. J. Clin. Pathol. 143,336–343 (2015}